InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,718.57
(
0.28%
)
US TECH 100
19,312.80
(
0.08%
)
Dow Jones
42,124.65
(
0.15%
)
Brent Oil
74.08
(
0.47%
)
Bitcoin
63,290.84
(
-0.06%
)
Post# of 253199
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120482
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: willyw post# 222221

Tuesday, 11/13/2018 12:13:22 PM

Tuesday, November 13, 2018 12:13:22 PM

Post# of 253199
ABBV/ENTA—The GT3-cirrhotic cohort is still in progress, according to today’s PR (in your post).

If it turns out that 8 weeks of Mavyret suffices for cirrhotic patients of any genotype, it will be quite a coup for ABBV/ENTA.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up